OnCore Login

Return to Trial Database

HCRN-GI00-16

A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation Therapy and Celecoxib for Resectable Esophageal Cancer – HOG GI 00-16

Status

Study Completed

Cancer Type(s)

Esophageal

Study Contact

Publications

A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC)
  • R Govindan, N Fineberg, H McLeod, K Kesler, N Hanna, C Stoner, J Vinson, R Mantravadi, L Einhorn
A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results
  • P Mantravadi, N Fineberg, R Ansari, E Fox, P Helft, K Kesler, N Hanna, L Einhorn, C Stoner, R Govindan
A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results
  • P Mantravadi, N Fineberg, R Ansari, E Fox, P Helft, K Kesler, N Hanna, L Einhorn, C Stoner, R Govindan
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results
  • R Govindan, H McLeod, P Mantravadi, N Fineberg, P Helft, K Kesler, N Hanna, C Stoner, R Ansari, E Fox

Trial Locations

All sites in which the trial HCRN-GI00-16 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278